Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- PE label "Parthenos Entities" assertion.
- PE label "Parthenos Entities" assertion.
- GPL-2.0-or-later label "GPL-2.0-or-later|GNU General Public License v2.0 or later" assertion.
- GPL-2.0-or-later label "GPL-2.0-or-later | GNU General Public License v2.0 or later" assertion.
- CC-BY-NC-4.0 label "CC BY-NC 4.0 | Attribution-NonCommercial 4.0 International" assertion.
- JSON_Schema label "JSON Schema | JavaScript Object Notation Schema" assertion.
- HTTP label "HTTP | Hypertext Transfer Protocol" assertion.
- SAML1.1 label "SAML1.1|Security Assertion Markup Language 1.1" assertion.
- SAML1.1 label "SAML1.1 | Security Assertion Markup Language 1.1" assertion.
- ArgoGdac label "Argo GDAC | Argo GDAC FAIR implementation community" assertion.
- ENVRI label "ENVRI | Environmental Research Infrastructures" assertion.
- ArgoGdac label "Argo GDAC | Argo GDAC FAIR implementation community" assertion.
- ACTRIS-ASC label "ACTRIS ASC community | ACTRIS Atmospheric simulation chamber data centre unit" assertion.
- eLTER-RI label "eLTER RI community | European Long-Term Ecosystem, critical zone and socio-ecological Research Infrastructure" assertion.
- DANUBIUS label "DANUBIUS community" assertion.
- AnaEE_CREA label "AnaEE CREA community" assertion.
- ICOS_Carbon_Portal label "ICOS Carbon Portal | Integrated Carbon Observation System Data Portal" assertion.
- ICOS_Carbon_Portal label "ICOS Carbon Portal | Integrated Carbon Observation System Data Portal" assertion.
- LWERIC-MetadataCatalogue label "LifeWatch ERIC Metadata Catalogue" assertion.
- LWERIC-MetadataCatalogue label "LifeWatch ERIC Metadata Catalogue" assertion.
- MP label "Materials Project" assertion.
- OSTI-DOI label "U.S. Department of Energy Office of Scientific and Technical Information (OSTI) Data ID Service" assertion.
- Google-Dataset-Search label "Google Dataset Search" assertion.
- URI label "URI | Uniform Resource Identifier" assertion.
- SDN_CDI_search label "SDN-CDI-Search | SeaDataNet CDI search user interface" assertion.
- RDA_CTS label "RDA CTS | RDA Core Trust Seal Certification" assertion.
- RDA_CTS label "RDA CTS | RDA Core Trust Seal Certification" assertion.
- metadata-schema-wf-test label "Metadata Schema WF Test" assertion.
- worldfair_project_communities label "WorldFAIR Project Communities" assertion.
- wf-wp06-socialsurveys label "WorldFAIR WP06 Social Surveys" assertion.
- wf-wp08-urbanhealth label "WorldFAIR WP08 URBAN HEALTH" assertion.
- CMIP6TOU label "CMIP6: Terms of Use" assertion.
- CMIP6 label "Climate Model Intercomparison Project phase 6 controlled vocabulary" assertion.
- CMIP6-data label "WRCP Climate Model Intercomparison Project phase 6 data" assertion.
- ESGF label "Earth System Grid Federation" assertion.
- EPND-CS1-SHACL-Template label "EPND CS1 SHACL Template | Shape constraint language template for EPND Case study 1" assertion.
- EPND-CS1-ATN label "European platform for neurodegenerative diseases, case study 1 on amyloid, tau and neurodegeneration " assertion.
- EPND label "European Platform for Neurodegenerative Diseases" assertion.
- DB01221 label "Ketamine" assertion.
- DB01221 label "Ketamine" assertion.
- DB01221 label "Ketamine" assertion.
- DB01221 label "Ketamine" assertion.
- DB01221 label "Ketamine" assertion.
- DB01221 label "Ketamine" assertion.
- DB01221 label "Ketamine" assertion.
- DB01221 label "Ketamine" assertion.
- DB01221 label "Ketamine" assertion.
- DB01221 label "Ketamine" assertion.
- DB01221 label "Ketamine" assertion.
- DB01221 label "Ketamine" assertion.
- DB01221 label "Ketamine" assertion.
- DB01221 label "Ketamine" assertion.
- association label "Ketamine remains an off-label treatment for treatment-resistant depression with factors that limit widespread use including its dissociative effects and abuse potential." assertion.
- context label "Adults" assertion.
- aggregator_knowledge_source label "aggregator knowledge source - An intermediate aggregator resource from which knowledge expressed in an Association was retrieved downstream of the original source, on its path to its current serialized form." assertion.
- context label "adults" assertion.
- association label "One of the off-label drugs that have an antidepressant effect is amantadine. The molecular mechanism of amantadine’s antidepressant action is not yet fully understood as the drug exerts its pharmacological effects through diverse brain signaling systems such as dopaminergic, noradrenergic, glutamatergic, and opioid systems. All patients treated with amantadine improved their depressive symptoms after 1 week of treatment." assertion.
- DB00915 label "Amantadine" assertion.
- context label "Adults" assertion.
- association label "Paroxetine is not FDA approved for use in children and adolescents less than 18 years of age; however, clinicians do use off-label in this group." assertion.
- MONDO_0001098 label "separation anxiety disorder" assertion.
- context label "Adults" assertion.
- association label "Paroxetine is not FDA approved for use in children and adolescents less than 18 years of age; however, clinicians do use off-label in this group." assertion.
- MONDO_0005929 label "postpartum depression" assertion.
- context label "Adults" assertion.
- association label "There are other off-label uses of imipramine as in the treatment of chronic neuropathic pain and panic disorder." assertion.
- context label "Adults" assertion.
- association label "Recently, off label use of modafinil (MOD), an approved medication for treatment of sleep disturbances, has been tested as a therapeutic for cocaine and methamphetamine use disorder. Positive results have been found in subjects dependent on psychostimulants without concurrent abuse of other substances." assertion.
- DB00745 label "Modafinil" assertion.
- DB00745 label "Modafinil" assertion.
- context label "Adults" assertion.
- association label "Desipramine is a secondary amine tricyclic antidepressant that is FDA approved for the treatment of depression. This drug has off-label use to treat bulimia nervosa, irritable bowel syndrome, neuropathic pain, overactive bladder, post-herpetic neuralgia, and ADHD." assertion.
- DB01151 label "Desipramine" assertion.
- DB01151 label "Desipramine" assertion.
- DB01151 label "Desipramine" assertion.
- DB01151 label "Desipramine" assertion.
- DB01151 label "Desipramine" assertion.
- DB01151 label "Desipramine" assertion.
- context label "Children and adolescents" assertion.
- association label "It is also commonly used as an off-label medication to treat children and adolescents with bipolar depression, although the FDA has not approved quetiapine for this purpose." assertion.
- context label "Adults" assertion.
- association label "Trazodone is also used off-label for anxiety, Alzheimer disease, substance abuse, bulimia, and fibromyalgia due to its serotonergic receptor antagonism and serotonin reuptake inhibiting effects." assertion.
- context label "Adults" assertion.
- association label "In this activity, augmentation and adjunctive strategies involving atypical antipsychotics, as well as off-label options including buspirone, stimulants, thyroid hormone, and lithium, are reviewed. ." assertion.
- context label "Adults" assertion.
- association label "It also has off label use as monotherapy or adjunctive therapy for the treatment of mania, restless leg syndrome, insomnia, tardive dyskinesia, and REM sleep behavior disorder." assertion.
- MONDO_0010096 label "tardive dyskinesia (disease)" assertion.
- context label "Adults" assertion.
- association label "It also has off label use as monotherapy or adjunctive therapy for the treatment of mania, restless leg syndrome, insomnia, tardive dyskinesia, and REM sleep behavior disorder." assertion.
- MONDO_0005937 label "REM sleep behavior disorder" assertion.
- context label "Adults" assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- context label "Adults" assertion.
- association label "Sedating antidepressants (e.g., amitriptyline, trazodone, mirtazapine) are often prescribed off-label as sleeping aids" assertion.
- context label "Children and adolescents" assertion.
- association label "Melatonin (97%), trazodone (81%), and quetiapine (73%) were rated by a majority of respondents as effective. Doxepin, zaleplon, tricyclic antidepressants, zolpidem, or lorazepam were rarely prescribed due to lack of evidence and/or concerns about adverse effects, long-term safety, suitability for youth, suicidality, and dependence/tolerance." assertion.
- context label "adults" assertion.
- association label "Other off-label therapies that have been used to treat HSDD include transdermal testosterone for peri- and post-menopausal women, and oral bupropion and buspirone" assertion.
- context label "adults" assertion.
- association label "TCAs can serve as first-line or augmenting drugs for neuropathic pain, headache, migraine, gastrointestinal syndromes, fibromyalgia, pelvic pain, insomnia, and psychiatric conditions other than depression" assertion.